Corrie's Shared Resources

Myeloid S1P1 Deletion Reduces Inflammation and Fibrosis in MASH Without Altering Steatosis
Metabolic dysfunction-associated steatohepatitis (MASH) is driven by immune-mediated hepatic inflammation, triggered in part by lipid dysregulation, especially elevated palmitic acid,...

FDA Approves Resmetirom for MASH
Resmetirom received accelerated FDA approval in March 2024 for treating metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced fibrosis (F2-F3),...

Recommending Non-invasive Liver Disease Assessments
Chronic liver disease (CLD) causes approximately two million deaths annually and presents a major global health burden. Because most severe...

Liver Biopsy Evaluation in MASH
During recent decades, the metabolic dysfunction-associated steatohepatitis (MASH) field has witnessed several paradigm shifts, including the recognition of liver fibrosis...

Advancements in MASLD Diagnosis: Non-Invasive Tools
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as NASH, is a growing health concern due to its association with...

GLP-1 Agonists’ Potential for Fibrosis Regression
In a recent review, researchers examined the molecular and clinical effects of glucagon-like peptide 1 (GLP-1) receptor agonists in treating...